CDH1 and neoplasm: In vivo administration of doses acting on metastases causes a decrease in the adhesion molecules ICAM-1 and E-cadherin on tumor cells, which under these experimental conditions, in addition to controlling metastasis spread, are responsible for reducing lymphocyte infiltration of the primary tumor and decreasing the ability of splenocytes to bind to tumor cells [45].